Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Because they are targeting very high TGs. That indication doesn't require CVD. Same as Marine indication.
You are not looking at it in a right way. It's irrelevant when Anchor trial was completed. What matters is when they can start selling this drug taking market share away from competitors including V. This can happen in 2 years time frame. Moreover, there's a good chance BP will aquire that company/product and things will get even tougher.
Ok. Let's see. The drop started at $3.50 and ended at $3.73. He sold @$3.00
Selling into the drop is very different from predicting one and acting accordingly. He just got fooled out of his shares. Typical sucker.
I agree. And if you recall it was company's justification for adding 2nd IA to expedite final read out process.
I'm not sure where you pulled 7 years from. But they can get FDA within 2 years.
More competition in the current indication on the horizon. V desperately needs that CVD reduction label.
https://globenewswire.com/news-release/2018/06/28/1531353/0/en/Gemcabene-Meets-Primary-Endpoint-in-INDIGO-1-Study-of-Severe-Hypertriglyceridemia-SHTG-Patients.html
He's too "disciplined" to admit his mistakes.
Is it too soon to say FFS got it wrong AGAIN!
Maybe he should stick to fishing ??
Agreed.
I have a better question. At what point Amarin can submit sNDA for RI indication? After top line results or complete data release? I'm sure FDA will want a complete data set in application package.
Rebalancing should be done by now especially if you consider settlement period for purchased/sold equities.
Full RAW data that needs to be organized, analyzed, and presented property. That takes time.
Raf/Kiwi, both of you just like kids.
There won't be any bidding war without good results. The better the results the higher valuation and BO price.
Imagine if Amarin drops 80% on failed RI. Kiwi & FFS will be the only people posting here. Lol
Mrmainstreet,
This binary is somewhat different. It will either make or break the company for good. Not many investors have stomach for this kind of trade. That's why I think many are watching from the fence. If RI succeeds, I expect PPS to explode and run for day/weeks as investors/funds will rush in.
Now regarding run-up into results. Remember we had false run-up in January and people got burned, thanks to dilution and Insiders greed.
I think this sent a wrong message and investors are more cautious now to jump in.
I still think the run up is possible as we still technically have 3 months before the end of Q3 (although, I don't think the data will be released that late). Additionally, run-ups happen a lot quicker these days. Stocks can easily jump 50-100% in a matter of days in anticipation of good news.
As many here have said it's all about RI. It would be nice to jump from the higher point on good RI results but in the end of the day it's really irrelevant if you are holding through the results as RI results will determine Amarin' value for the foreseeable future.
IBB is down 2%. We are at the bottom. The uptrend should start any day now.
Sorry. I misunderstood you. I thought you moved money from your trading account to IRA account.
And if RI fails you won't be able to write off any loss...
Don't forget Kowa partnership ends after RI results.
No need to complicate BO negotiations. lol
Of course they can get greedy again and we all know how it worked out for the shareholders last time.
But first things first let's get through RI results.
Marzan,
If you haven't noticed Amarin paid Mochida for IP. Mochida isn't going to buy Amarin.
IMO If RI is a huge success, Amarin will be sold for around $10bil.
$280 PPS isn't happening.
Any updates on ITC case?
Kiwi,
You can add me to the list. Bought more last week and today.
FFS,
Everything you listed was known last week when you were super bullish. The only thing changed is the stock broke support. So what? Stocks do it all the time and come back easily. In fact, MM knows that people like you are watching for those supports so they manipulate the share price below key supports to take advantage of triggered stop loss and panic selling.
Now back to fundamentals.
Diluting earlier this year was simply a risk management step in case things go sideways. Even if management is 100% confident in RI results, it's still made sense to raise some cash. Especially since they are spending these money now on advertisement, settling lawsuit with Teva, buying IP from Mochida, and increasing inventory. Now if management knew RI is going to fail they would raise a lot more cash and spend nothing.
Collaboration with Mochida gives Amarin access to IP. I don’t see anything negative in this. Especially if management is serious about going after additional indications.
Winning ITC case will help to keep DS out and do not allow them to capitalize on RI success. Again I don’t see anything negative here. Only upside.
The bottom line there was no leak and RI results are likely to be good if not excellent based on everything we know about EPA.
Btw I added last week. The wait is almost over. We'll know soon enough what wins in the end TA or fundamentals.
I bet on fundamentals.
Dude, your analogy would make sense if not for Jelis, and high Tg subgroups in other trials.
Try again.
FFS, Looks like volcano eruption will happen without you...
I believe the DB is still locked so no leak. If DMC was leaking we would see it after 1st IA.
Trying to predict RI results based on Amarin stock TA is interesting approach to say the least.
You didn't get his point. He was simply correcting other post.
Today, tomorrow, it's all irrelevant. What's really matter is the price the day RI results are out.
Something tells me FFS will remember this day for a long time if he's stubborn enough to stay out, of course. lol
Exactly. The trial runs longer with added patients means better efficacy to me.
We'll know for sure soon enough.
Don't forget it's end of the quarter. Funds re-shuffle their holdings, especially those that didn't perform well.
I'm confident we'll see $4 sooner than we see $2.
Only 3mil shares traded out of 300mil outstanding and you call it a leak? A big fund bailing? Come on! You should know better a true leak would result in a lot more blood and in options too.
I added today!
Management buying shares? Please!
You better hope they don't sell in the coming days.
HD,
I believe 100% of patients enrolled had Tgs between 150 and 500.
According to your post 38% had Tgs between 150 and 200.
That means 62% had Tgs between 200 and 500.
Does sound right?
Also, I believe a majority of patients with Tgs <200 were enrolled early in the trial.
Just do the bell curve. lol